Activity of ceftazidime–avibactam against multidrug-resistance Enterobacteriaceaeexpressing combined mechanisms of resistance

Antimicrobial resistance in Enterobacteriaceaeis increasing worldwide and is making treating infections caused by multidrug-resistant Enterobacteriaceaea challenge. The use of β-lactam agents is compromised by microorganisms harboring extended-spectrum β-lactamases (ESBLs) and other mechanisms of resistance. Avibactam is a non β-lactam agent that inhibits clinically relevant β-lactamases, such as ESBL and AmpC. The ceftazidime–avibactam combination (CAZ-AVI) was recently approved for use in certain complicated infections, and may provide a therapeutic alternative for infections caused by these microorganisms.